
Intismeran autogene plus pembrolizumab cut the risk of recurrence or death by 42% vs pembrolizumab alone in resected stage IIB-IV melanoma.
Obtaining blood biopsies instead of invasive tissue biopsies may be less risky for patients, faster, and cost less.
A recent study